NCT02393859 2024-05-29Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Completed111 enrolled 23 charts 1 FDA